49.40MMarket Cap-581P/E (TTM)
0.860High0.730Low1.57MVolume0.830Open0.821Pre Close1.21MTurnover5.65%Turnover RatioLossP/E (Static)65.88MShares2.09852wk High0.68P/B20.88MFloat Cap0.73052wk Low--Dividend TTM27.84MShs Float17.880Historical High--Div YieldTTM15.87%Amplitude0.730Historical Low0.767Avg Price1Lot Size
IO Biotech Stock Forum
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
IO Biotech announced promising Phase 2 results for its cancer vaccine IO102-IO103 combined with KEYTRUDA® in first-line metastatic lung cancer treatment. The study showed a 55% unconfirmed/48% confirmed overall response rate and 8...
loading...
No comment yet